BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 28946669)

  • 1. Blocking of the Ubiquitin-Proteasome System Prevents Inflammation-Induced Bone Loss by Accelerating M-CSF Receptor c-Fms Degradation in Osteoclast Differentiation.
    Lee K; Kim MY; Ahn H; Kim HS; Shin HI; Jeong D
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28946669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific targeting of PKCδ suppresses osteoclast differentiation by accelerating proteolysis of membrane-bound macrophage colony-stimulating factor receptor.
    Kim MY; Lee K; Shin HI; Jeong D
    Sci Rep; 2019 May; 9(1):7044. PubMed ID: 31065073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-c-fms Antibody Prevents Osteoclast Formation and Bone Resorption in Co-Culture of Osteoblasts and Osteoclast Precursors In Vitro and in Ovariectomized Mice.
    Nara Y; Kitaura H; Ogawa S; Shen WR; Qi J; Ohori F; Noguchi T; Marahleh A; Pramusita A; Kinjo R; Mizoguchi I
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32854340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-c-Fms antibody inhibits lipopolysaccharide-induced osteoclastogenesis in vivo.
    Kimura K; Kitaura H; Fujii T; Hakami ZW; Takano-Yamamoto T
    FEMS Immunol Med Microbiol; 2012 Mar; 64(2):219-27. PubMed ID: 22067001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function.
    Zavrski I; Krebbel H; Wildemann B; Heider U; Kaiser M; Possinger K; Sezer O
    Biochem Biophys Res Commun; 2005 Jul; 333(1):200-5. PubMed ID: 15936724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.
    Watanabe K; Hirata M; Tominari T; Matsumoto C; Fujita H; Yonekura K; Murphy G; Nagase H; Miyaura C; Inada M
    J Biol Chem; 2016 Sep; 291(40):20891-20899. PubMed ID: 27539855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuromedin B and its receptor silencing suppresses osteoclast generation by modulating precursor proliferation via M-CSF/c-Fms/D-type cyclins.
    Yeo CE; Kang WY; Seong SJ; Cho S; Lee HW; Yoon YR; Kim HJ
    Exp Cell Res; 2017 Oct; 359(1):112-119. PubMed ID: 28780306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rab11A Functions as a Negative Regulator of Osteoclastogenesis through Dictating Lysosome-Induced Proteolysis of c-fms and RANK Surface Receptors.
    Okusha Y; Tran MT; Itagaki M; Sogawa C; Eguchi T; Okui T; Kadowaki T; Sakai E; Tsukuba T; Okamoto K
    Cells; 2020 Oct; 9(11):. PubMed ID: 33142674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity.
    El Hajj Dib I; Gallet M; Mentaverri R; Sévenet N; Brazier M; Kamel S
    Eur J Pharmacol; 2006 Dec; 551(1-3):27-33. PubMed ID: 17049513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. c-Fms signaling mediates neurofibromatosis Type-1 osteoclast gain-in-functions.
    He Y; Rhodes SD; Chen S; Wu X; Yuan J; Yang X; Jiang L; Li X; Takahashi N; Xu M; Mohammad KS; Guise TA; Yang FC
    PLoS One; 2012; 7(11):e46900. PubMed ID: 23144792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
    Michael H; Härkönen PL; Väänänen HK; Hentunen TA
    J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosines 559 and 807 in the cytoplasmic tail of the macrophage colony-stimulating factor receptor play distinct roles in osteoclast differentiation and function.
    Feng X; Takeshita S; Namba N; Wei S; Teitelbaum SL; Ross FP
    Endocrinology; 2002 Dec; 143(12):4868-74. PubMed ID: 12446614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.
    Polzer K; Neubert K; Meister S; Frey B; Baum W; Distler JH; Gückel E; Schett G; Voll RE; Zwerina J
    Arthritis Rheum; 2011 Mar; 63(3):670-80. PubMed ID: 21360496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib inhibits human osteoclastogenesis.
    von Metzler I; Krebbel H; Hecht M; Manz RA; Fleissner C; Mieth M; Kaiser M; Jakob C; Sterz J; Kleeberg L; Heider U; Sezer O
    Leukemia; 2007 Sep; 21(9):2025-34. PubMed ID: 17581612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An anti-c-Fms antibody inhibits osteoclastogenesis in a mouse periodontitis model.
    Kimura K; Kitaura H; Fujii T; Ishida M; Hakami ZW; Takano-Yamamoto T
    Oral Dis; 2014 Apr; 20(3):319-24. PubMed ID: 23651419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dual-specific macrophage colony-stimulating factor antagonist of c-FMS and αvβ3 integrin for osteoporosis therapy.
    Zur Y; Rosenfeld L; Keshelman CA; Dalal N; Guterman-Ram G; Orenbuch A; Einav Y; Levaot N; Papo N
    PLoS Biol; 2018 Aug; 16(8):e2002979. PubMed ID: 30142160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro.
    Marahleh A; Kitaura H; Ishida M; Shima K; Kishikawa A; Ogawa S; Shen WR; Qi J; Ohori F; Noguchi T; Nara Y; Mizoguchi I
    J Vis Exp; 2019 Mar; (145):. PubMed ID: 30933072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.